u/Daniel-Briefio

I continue to share some pre-session thoughts on #ESCCongress. Hot Line 1 has 5 trials for discussion. Here are my thoughts for four of them:

CARDIO-TTRansform is about Transthyretin amyloid cardiomyopathy, a rare disease, unfortunately they did not meet their endpoints.

ACACIA-HCM examines non-obstructive Hypertrophic Cardiomyopathia,

SINGLE-AF is a Korean study on anticoagulation in AF patients (very relevant), and

POET-II - is about duration of antibiotic therapy in Endocarditis with POET-II being potentially impacting clinical practice and guideline - this would be good for patients.

You can read my full thoughts here: https://luminary.to/s/64eb5480-0b17-4a87-9987-36e80c02d1fa?code=ESC2026

ESC 2026 opens in Munich soon. This year's Hot Line programme is the largest ever - 46 pivotal trials. There are a some trials which have the potential to change clinical practice, I would love to know, which you think are worth watching?

For me STAREE and PREMIUM are quite interesting with lots of practical implication.

With 46 trials it is quite hard to keep the overview of all the pivotal trials - I put together a 1-pager to help me navigate the sessions. Maybe helpful to you too: https://luminary.to/s/245068d7-9d15-4e3e-8855-fd5cb4e2b4c4?code=ESC2026

#ESCCongress #Cardiology